A Year in Oncology: A review of 2021 drug approvals in US, Europe and Japan
Whilst the global COVID-19 pandemic continued throughout 2021, new oncology drug and indication approvals maintained momentum across the US, Europe and Japan. These included continued roll-out and label expansions of Immuno-Oncology (I-O) therapies, along with treatments approved in Japan ahead of other global regions.
The Ipsos Oncology CoE has compiled this information in an easy-to-digest infographic, which includes:
- A round-up of the total number of approvals in each oncology indication across each region
- Key ‘milestone’ approval events, by month
- Reference to additional biosimilar and generic approvals
Download the full infographic.
Download
